Full Year 2025 ALS Ltd Earnings Call Transcript
Key Points
- ALS Ltd (CPBLF) reported strong revenue growth of 16% to $3 billion for fiscal year '25, demonstrating the strength of its diversified and resilient operating model.
- The company achieved a robust EBIT margin of 19.1% excluding recent acquisitions, aligning with its strategic plan objectives.
- Life Sciences division delivered industry-leading organic growth of 9.8% in Environmental, benefiting from increased testing demand for PFAS.
- ALS Ltd (CPBLF) maintained a strong cash conversion rate of 95% of underlying EBITDA, supporting its capital framework and growth journey.
- The company declared a final dividend of $19.7 per share, reflecting a 60% payout ratio, supported by solid performance and liquidity.
- The underlying EBIT margin declined to 17.2% due to dilution from recent acquisitions and cyclical pricing pressures in Minerals.
- Return on capital employed decreased to 18.9%, impacted by recent acquisitions.
- Underlying net profit after tax declined by 1.4% to $312.1 million, although it increased by 2.8% on a constant currency basis.
- The company's leverage ratio was at the upper end of its target range at 2.3 times, reflecting investment and integration activities.
- ALS Ltd (CPBLF) faces a $5 million to $10 million EBIT risk in fiscal year '26 due to changes in Mexican pharmaceutical testing regulations.
Good day, and thank you for standing by. Welcome to ALS Limited full year 2025 results investor presentation. (Operator Instructions) Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to your first speaker today, Mr. Malcolm Deane, Chief Executive Officer and Managing Director of ALS. Please go ahead, sir.
Thank you very much, and good morning, and thank you, everyone, for taking the time and joining today's briefing. It's really good to be back with all of you to share what we believe has been a strong fiscal year '25 financial performance for ALS. As usual, I'm joined by our Chief Financial Officer, Stuart Hutton.
Earlier today, we released our fiscal '25 results and an equity raising to fund an extensive had laboratory network expansion and our future inorganic growth, which we will cover off on after the fiscal year '25 results. So we will aim to hit the highlights and not necessarily talk through
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
